FLT3LG and non-small cell lung carcinoma: The results revealed significant differences in FLT3LG expression between patients with different pathological stages (stage III vs. normal, P < 0.05) and patients with different pathological T stages (T1 vs. T2, P < 0.001; and T2 vs. normal, P < 0.05) in NSCLC, including both LUAD and LUSC.